See up to 3 months of CUE. The 7-day demo opens the 1M and 3M ranges and puts CUE on your watchlist.
Start 7-day demoLatest CUE insider trades
About Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. is an SEC registrant, filing under CIK 0001645460, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
CUE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 15 | 86,790 | $2.43M |
| Grant or award | 2 | 37,300 | |
| Option exercise | 6 | 282,044 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CUE insider transactions (Form 4)
1439 Form 4 filings on record, the earliest from Nov 29, 2024, newest first. Filing history page 2 of 2.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Pasha Sarraf | Grant or award | Stock Option (right to buy) | 24,400 | $0.00 | - | |
| Pasha Sarraf | Open-market purchase | Common Stock | 4,229 | $0.31 | $1K | |
| Pasha Sarraf | Open-market purchase | Common Stock | 77,148 | $0.30 | $23K | |
| Pasha Sarraf | Open-market purchase | Common Stock | 86,947 | $0.32 | $28K | |
| Pasha Sarraf | Open-market purchase | Common Stock | 78,116 | $0.31 | $24K | |
| Pasha Sarraf | Open-market purchase | Common Stock | 77,417 | $0.30 | $23K | |
| Colin Sandercock - Officer | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Colin Sandercock - Officer | Grant or award | Stock Option (right to buy) | 70,000 | $0.00 | - | |
| Lucinda Warren - Officer | Grant or award | Stock Option (right to buy) | 125,000 | $0.00 | - | |
| Daniel G. Baker - Officer | Grant or award | Stock Option (right to buy) | 50,000 | $0.00 | - | |
 Usman Azam - Officer | Grant or award | Stock Option (right to buy) | 1,875,000 | $0.00 | - | |
| Jill Marie Broadfoot | Grant or award | Stock Option (right to buy) | 48,800 | $0.00 | - | |
| Daniel R. Passeri - Officer | Open-market purchase | Common Stock | 30,000 | $1.03 | $31K | |
| Daniel G. Baker - Officer | Grant or award | Stock Option (right to buy) | 200,000 | $0.00 | - |
Recent CUE Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Shao-Lee Lin | Officer, Director | 11,087 | $305K | View on EDGAR | |
| Sumita Ray | Officer, CORPORATE SECRETARY | 1,844 |
CUE insider trading FAQ
What is the latest insider trade for CUE?
Cue Biopharma, Inc. (CUE) had 8 insider filings in the last 90 days, with the most recent on 15 October 2026. The full record for CUE runs to 39 Form 4 filings, the earliest from 29 November 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CUE stock?
No insider purchases of CUE were filed in the last 90 days. 8 purchases are on record for this company.
How many insiders are selling CUE stock?
15 insider sales of CUE were filed in the last 90 days, totaling $2.43M.
Where can I see CUE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CUE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Sumita Ray view on EDGAR
- - Michael Vincent Meluzio view on EDGAR
- - Shao-Lee Lin view on EDGAR
- - Pasha Sarraf view on EDGAR
- - Pamela Garzone view on EDGAR
- - Sumita Ray view on EDGAR
- - Michael Vincent Meluzio view on EDGAR
- - Shao-Lee Lin view on EDGAR
- - James M. Ahlers view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CUE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CUE with a 7-day demo
- CUE on your watchlist
- Every CUE Form 4 filing on record
- Up to 3 months of CUE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
